Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples